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ABSTRACT 
 
Muscarinic acetylcholine receptors, a G protein-coupled receptor, are responsible 
for a wide range of diseases. We predicted the 3D structure of the human M1 muscarinic 
receptor using the MembStruk method and validated its binding sites for 10 agonists and 
antagonists using the HierDock method. The predicted binding sites, the intramolecular 
contacts that stabilize the receptor conformation, and the in silico mutagenesis results, 
agree well with mutagenesis data. The calculated relative binding energies correlate well 
with measured binding affinities. In addition, the predicted binding sites provide a 
structural basis for the large reduction in ligand binding affinity and signaling efficacy by 
Trp 157 and Pro 159 mutations, which was not previously explained by homology models. 
The predicted binding sites illustrate the importance of aromatic residues in ligand binding 
through extensive cation-π and aromatic-aromatic interactions, with new mutation 
candidates suggested. The predicted M1 structure improves our understanding of the 
muscarinic receptors, offers a basis for structure based drug design, and is a successful step 
toward applying these procedures in predicting the structures of other muscarinic receptor 
subtypes. 
 
We used high-level quantum mechanics to quantify cation-π interactions in the 
crystal structure of carbamylcholine binding to Acetylcholine-binding Protein, a nicotinic 
receptor homolog. The calculated effects of fluorinated unnatural amino acid substitutions 
also correlate excellently with experimental EC50 data, suggesting that quantum mechanics 
 v 
can accurately predict cation-π binding in a protein environment and provides a good 
model system in developing force fields to better describe cation-π interactions. 
 
Histidines are known to modulate pH responsive binding. We designed a series of 
histidine derivatives by substituting its imidazole ring with functional groups that are small 
in size and lack the ability to form hydrogen bonds. Quantum mechanical calculations of 
the acid dissociation constants (pKa) show that these substitutions shift the histidine pKa 
upward or downward. We report a list of histidine derivatives and their corresponding pKa 
values that can be used in designing tumor specific drugs (e.g. HER2-Herceptin antibody), 
drug delivery through pH sensitive hydrogels, drug recycling, catalysis, and biosensors 
development. An example of how these unnatural histidines can be used is illustrated with 
2-methyl histidine incorporated in a c-Myc-Max heterodimer.  
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Part 1 
 
Structure and Function Prediction of Human Muscarinic 
Acetylcholine Receptor 1 (M1), a G Protein Coupled 
Receptor 
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A b s t r a c t  
 
The five subtypes of muscarinic acetylcholine receptors are implicated in the 
pathogenesis of a wide range of diseases including cognitive dysfunction and smooth 
muscle disorder.  Availability of the 3D structure of these receptors would greatly enhance 
subtype specific drug design. In this study, we predicted the structure of the human 
muscarinic acetylcholine receptor 1 (M1) using the MembStruk computational method and 
validated this structure using the HierDock docking method to predict the ligand-binding 
sites for 10 agonists and antagonists. The predicted binding sites, the intramolecular 
contacts that stabilize the receptor conformation, and the results of in silico mutagenesis 
agree well with experimental mutagenesis data. The calculated relative binding energies 
also correlate well with measured binding affinities. The predicted binding site of 
antagonists is located between TM helices 3, 4, 5, 6, and 7, whereas the agonist binding site 
involves residues from helices 3, 6, and 7.  In addition, the antagonist binding sites provide 
a structural basis for the large reduction in ligand binding affinity and signaling efficacy by 
mutations of Trp 157 [4] and Pro 159 [4], which were not previously explained by other 
homology based models of M1. The numbers shown in the square parentheses are the TM 
helix numbers. Our prediction suggests that Trp 157, directly participates in ligand binding, 
instead of forming a secondary ligand docking site, while Pro 159 provides an indirect 
conformational switch to position Trp 157. In addition to the critical Asp 105 [3], several 
aromatic residues including Tyr 381 [6], Tyr 404 [7], Tyr 408 [7] are important in binding 
the ligand quaternary ammonium head group through cation-π interactions with a geometry 
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similar to that in the nicotinic acetylcholine receptor crystal structure complex. Our 
results also suggest that upon binding of ligands with a charged tertiary amine head group, 
proton transfer from the ligand to Asp 105 [3] might occur. In addition, an extensive 
aromatic network involving Tyr 106 [3], Trp 157 [4], Phe 197 [5], Trp 378 [6], and Tyr 381 
[6] is important in stabilizing the antagonists binding sites. For antagonists with two 
terminal aromatic rings, this aromatic network extends to Trp 164 [4], Tyr 179 
[extracellular loop 2], and possibly Phe 391 [6]. Asn 382 [6] forms hydrogen bonds with 
selected antagonists. Tyr 381 [6] and Ser 109 [3] form hydrogen bonds with the ester 
moiety of acetylcholine, which binds in the gauche conformation. Many residues whose 
Ala mutations were shown to decrease the receptor stability and/or induce agonist-
independent basal signaling activity also form favorable intramolecular contacts in the 
predicted structure. This study provides the structural insights for improved 
understanding of the M1 receptor and its binding sites and is a successful step 
toward applying these procedures to predict the structures and function of the other 
four muscarinic receptor subtypes, which should, in turn, enable the development of 
subtype-specific agonists and antagonists with reduced side effects. 
 
  
11 
C h a p t e r  1  
INTRODUCTION 
 
The pharmacological action of acetylcholine is divided into two main categories: 
muscarinic and nicotinic (1). The nicotinic acetylcholine receptors belong to the family of 
ligand-gated ion channels. The muscarinic acetylcholine receptors, which belong to the G 
protein-coupled receptor (GPCR) family, play a critical role in mediating the metabotropic 
action of acetylcholine. Among the five subtypes of muscarinic receptors, the M1, M3, and 
M5 receptors are stimulatory and couple preferentially to G-proteins of the Gq/G11 class, 
which leads to phosphoinositide breakdown. The M2 and M4 receptors are inhibitory and 
couple primarily to G-proteins of the Gi and Go classes, leading to adenylate cyclase 
inhibition that reduces the cytoplasmic concentrations of cyclic AMP (1). The M1-M5 
receptor knockout mice study suggested that the M1 receptor modulates neurotransmitter 
signaling in the cortex and hippocampus. The M2 receptor mediates tremor, hypothermia, 
and auto-inhibition of acetylcholine release in several brain regions. The M3 receptor is 
involved in exocrine gland secretion, smooth muscle contractility, and weight gain. The M4 
receptor modulates dopamine activity in motor tracts and acts as an inhibitory auto-receptor 
in the striatum. The M5 receptor modulates central dopamine function and the tone of 
cerebral blood vessels (2).  
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The muscarinic receptors are responsible for a wide range of diseases, including 
cognitive dysfunctions such as Alzheimer’s disease (3), schizophrenia, and Parkinson’s 
disease (2), as well as smooth muscle disorders such as overactive bladder, irritable bowel 
syndrome, and chronic obstructive pulmonary disease (1). Significant effort has been 
focused on identifying M1 agonists and M2 antagonists of muscarinic acetylcholine 
receptors as a potential treatment of Alzheimer’s disease by stimulating the cholinergic 
system (3, 4). The rationale for developing M1 agonists was based on the role of 
acetylcholine in learning and memory function and the finding that cholinergic neurons 
degenerated in Alzheimer’s patients. In addition, M1 receptors promote α-secretase 
activity, which results in the secretion of non-toxic peptide fragments of amyloid precursor 
protein and decreased Aβ deposition (3, 4). 
 
Despite the extensive development of muscarinic M1 receptor agonists for the 
treatment of cognitive dysfunctions, many drug candidates were discontinued because of 
the occurrence of undesirable side effects from cross reactivity to other receptor subtypes 
(3). The high sequence homology between muscarinic receptor subtypes contributes to the 
relatively poor selectivity of compounds that display muscarinic agonist activity. Despite 
the importance of muscarinic receptors, no 3D crystal structure is currently available for 
any muscarinic receptor subtype that could enable structure-based drug design to develop 
drugs with improved subtype specificity and reduced side effects. To this date the only 
experimental 3D structure available for GPCR is bovine rhodopsin (5). The lack of crystal 
structures is because the GPCRs are bound to the membrane, making it difficult to express 
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them in sufficient quantities for crystallization. In addition, it is difficult to construct 
reliable homology models of muscarinic receptors because of the low sequence homology 
(16% overall sequence identity and 21% in the TM regions for M1 receptor) between 
bovine rhodopsin and muscarinic receptors. Because the binding site of 11cis-retinal in 
bovine rhodopsin is narrow, in building M1 homology models, manual adjustments of the 
TM helices or the second extra-cellular (EC2) loop positions were often required to fit the 
ligands, introducing biases to the model (6,7).  Attempts to use the M1 homology model in 
virtual ligand screening also generated poor hit rates for agonists and antagonists (6). 
Fortunately, extensive mutagenesis experiments and ligand binding data is available for the 
muscarinic receptors, especially the M1 receptor (8-12). 
  
We report here the predicted structure of human M1 muscarinic receptor using the 
Membstruk computational method.  MembStruk, unlike homology based models, does not 
use any information from the crystal structure of bovine rhodopsin. We then used the 
HierDock method to predict the ligand binding sites and calculated the binding energies of 
10 agonists and antagonists to the M1 receptor. The MembStruk and HierDock methods 
have been validated for bovine rhodopsin (13, 14), human β2 adrenergic receptor (15), 
human D2 dopamine receptor (16), and mouse and human olfactory receptors (17-20),  
where the predicted binding sites are in good agreement with the experimental results.  
 
In this study, the predicted M1 structure and the predicted binding sites of agonists 
and antagonists agree well with experimental results. The calculated relative binding 
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energies also correlate well with measured binding affinities. Among the 8 agonists and 
antagonists studied, agonists bind at a region between TM 3, 6, 7, whereas antagonists bind 
at a region between TM 3, 4, 5, 6, and 7, which overlaps with the agonists binding region. 
Our results show that Asp 105 [3] is essential in ligand binding. This effect is even more 
significant for ligands with basic tertiary amine than with quaternary ammonium head 
groups. The numbers shown within square parentheses are the TM helix to which the 
residue belongs.  Tyr 381 [6], Tyr 404 [7], Tyr 408 [7] are also important in stabilizing the 
ligand quaternary ammonium head group with cation-π interactions. The cation-π distances 
at the predicted M1 binding site are very similar to the ones in the nicotinic acetylcholine 
receptor crystal structure complex (21). Extensive aromatic networks involving Tyr 106 
[3], Trp 157 [4], Phe 197 [5], Trp 378 [6], and Tyr 381 [6] are important in stabilizing the 
antagonist binding sites. For antagonists with two terminal aromatic rings, the aromatic 
network extends to Trp 164 [4], Tyr 179 [extra-cellular loop 2], and possibly Phe 391 [6]. 
In addition to these favorable aromatic-aromatic interactions, Asn 382 [6] forms hydrogen 
bonds to antagonists such as NMS, pirenzepine, and QNB. Tyr 381 [6] and Ser 109 [3] 
form hydrogen bonds with the ester moiety of acetylcholine, which binds in the gauche 
conformation. In addition, many residues whose Ala mutations were shown to decrease the 
receptor stability and/or induce agonist-independent basal signaling activity form favorable 
intra-molecular contacts in the predicted structure.  
 
Chapter 2 of my thesis presents the results of the predicted M1 structure and its 
binding sites for the 10 agonists and antagonists studied. The results are compared with 
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available mutagenesis and ligand binding data. Several new mutation candidates are 
suggested. Possible mechanisms of receptor activation by comparing agonist and antagonist 
binding sites are discussed. Chapter 3 provides a detailed description of the methods used 
to predict the M1 structure, with several refinements to the Membstruk method listed. This 
study not only provides the structural insights for improved understanding of the M1 
receptor and its binding sites, but also is a successful step towards applying these 
procedures to predict the 3D structures and function of the other four subtypes of 
muscarinic receptors, which should, in turn, enable the development of subtype-specific 
agonists and antagonists with reduced side effects. 
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C h a p t e r  2  
TERTIARY STRUCTURE AND LIGAND BINDING SITES OF THE HUMAN M1 
RECEPTOR: EXPERIMENTAL VALIDATIONS AND NEW INSIGHTS  
 
Results 
Properties of the Predicted Human M1 Receptor Structure 
The three dimensional structure of M1 is shown in Fig. 1.  Among the residues 
whose Ala substitution (7) reduced the level of expression of M1 receptor binding sites by 
more than 30 fold to less than 3% of the wild type level (by rendering the receptor 
unstable), the conserved Trp 150 [4] points towards TM 2 and TM 3 (Fig. 2A) in our 
predicted structure, similar to its position in the bovine rhodopsin crystal structure.  Asp 71 
[2], the most conserved Asp across many GPCRs on TM2, is hydrogen bonded to Asn 43 
[1] (Fig. 2B).  Based on Ala mutagenesis experiments, Asp122 [3] in the conserved DRY 
sequence was suggested to make intra-molecular contacts whose integrity is important for 
efficient receptor folding (22).  In the predicted structure, Asp 122 [3] forms a salt bridge to 
both Arg 365 [6] and Arg 210 [5] at the intra-cellular end of the receptor (Fig. 2C). 
Mutation of Leu 116 [3] not only reduced the receptor expression level but also increased 
agonist affinity and raised constitutive activity, a phenotype suggested for residues forming 
intra-molecular contacts that are important in stabilizing the inactive state, but not the 
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activated state of the receptor (7). In our predicted structure, Leu 116 [3] is in the core of 
the receptor and contacts Phe 374 [6], which also contacts Asn 414 [7] (Fig. 2D).  Mutation 
of Phe 374 [6] and Asn 414 [7] on the M5 receptor, has been reported to cause a 10 fold 
decrease in the receptor expression level (7). Mutation of the residue equivalent to M1 Phe 
374 [6] in the M5 receptor was also reported to increase constitutive activity (7). The close 
proximity of Leu 116 [3], Phe 374 [6], and Asn 414 [7] in the predicted structure 
corresponds well to the experimental results where the His-substitution of these three 
residues formed a Zn2+ binding site in the ground state of the M1 receptor (Fig. 2D) (23). 
Note that the α-carbons of these three residues must be separated by less than 13 Å to allow 
the corresponding imidazole side chains to coordinate a metal ion (23).  The predicted α-
carbon distances among these residues are 7.7 Å, 8.4 Å, and 11.0 Å thus satisfying this 
criterion (Fig. 2D). Among other residues that also increased acetylcholine affinity and 
basal signaling activity (but to a lesser extent), Trp 405 [7] forms an inter-helical hydrogen 
bond with Thr 32 [1] (Fig. 2E), Ala 160 [4] forms a hydrophobic interaction with Thr 192 
[5] (Fig. 2F), residue shown to affect agonist but not antagonist binding (24), and Ser 120 
[3] points toward the core of the receptor and contacts both Leu 116 [3] and Phe 374 [6].  
Several inter-helical hydrogen bonds are present at the ligand binding sites (Fig. 3) in the 
predicted structure, including the ones between Asp 105 [3] and Tyr 408 [7], between Ser 
109 [3] and Tyr 381 [6], and between Tyr 389 [6] and Tyr 404 [7].   
 
The hydrophobicity profile of the multiple sequence alignment used for predicting 
the length of the TM regions of the M1 receptor is shown in Fig. 4. The position of 
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maximum hydrophobicity in the hydrophobicity profile is called the TM hydrophobic 
center. Fig. 5 lists the TM regions and the hydrophobic center of each helix predicted by 
Membstruk hydrophobicity profiling and capping procedures (14). The helical bending 
angles and helical tilt of the predicted M1 structure are listed in Fig. 6.  
 
Predicted Binding Sites for Agonists and Antagonists in Human M1 Receptor 
We have predicted the binding sites of 10 agonists and antagonists (shown in Fig. 7) 
and calculated their binding energies using the HierDock 2.0 method (13).  
 
Scanning the Entire M1 Receptor for Binding Sites 
To locate the binding site of the agonists and antagonists, the void region in the entire 
receptor structure was divided into 27 regions and the HierDock method was used for 5 
ligands in each box to determine the binding site.  The ligands used included NMS, QNB, 
acetylcholine, tetramethylammonium, and 4-DAMP. For each ligand, the best scoring five 
conformations in energy with at least 80% buried surface area were used to select the best 
regions for subsequent docking of all ligands. The positions of the top 2 best binding 
regions selected are shown in Fig. 8. All the 8 agonists and antagonists were subsequently 
docked into this best binding region and the binding energies calculated using HierDock 
2.0 method as briefed in the Methods section. 
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Predicted Binding Site for Antagonist N-methylscopolamine (NMS) 
Fig. 9 shows the predicted binding site of the antagonist, the active S-(−)-enantiomer of 
NMS, determined by HierDock. The predicted NMS binding site involves residues in TM 3 
to 7.  Figures 9A and 9B show that the NMS binds between TM helices 3, 4, 5, 6 and 7 in 
the predicted M1 receptor structure. Figure 9C shows the residues within 4 Å of the ligand 
in the predicted binding site of NMS. The charged quaternary ammonium headgroup forms 
a 3.5 Å salt bridge to Asp 105 [3].  It also interacts with the surrounding aromatic residues 
Tyr 404 [7], Tyr 408 [7], Trp 101 [3], and Tyr 381 [6] primarily through cation-π 
interactions (46). The hydroxylmethyl group on the tropic acid side chain of NMS is 
hydrogen-bonded to Asn 382 [6] at a distance of 2.9 Å. The carbonyl group of the ester 
moiety is hydrogen-bonded to Ser 109 [3] at a distance of 2.8 Å. The benzene group at the 
tropic acid side chain of NMS interacts with the surrounding aromatic residues Tyr 106 [3], 
Trp 157 [4], Trp 378 [6], and Phe197 [5].  Fig. 9C highlights the favorable aromatic-
aromatic interactions between the negatively charged carbon atoms at the NMS benzene 
ring and the positively charged hydrogen atoms of Tyr 106 [3] and Trp 157 [4] aromatic 
rings. 
 
Computational Ala Scanning Mutations for NMS Binding Site in the M1 Receptor 
We performed systematic mutation of the residues in the binding site of NMS (all residues 
within 6Å) to Ala and calculated the change in binding energy, to compare to the 
experimental Ala substitution mutagenesis data on NMS binding affinity. We observed that 
the Ala mutation of the following residues changes the binding energies by more than 5 
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kcal/mol: Asp 105 [3], Tyr 106 [3], Tyr 381 [6], Asn 382 [6], Tyr 404 [7], and Tyr 408 
[7]. All these residues were shown experimentally to affect NMS binding affinity by more 
than 30 fold (7).  
 
Predicted Binding Site for NMS Derivatives 
Fig. 10 shows the 4 Å binding site of three NMS derivatives shown in Fig. 7: N-
Methylatropine, N-Methylhomatropine, and N-Methylacetyltropine. These three 
derivatives of NMS also bind in the region between TM helices 3, 4, 5, 6 and 7. In N- 
Methylhomatropine, a methylene group bearing the hydroxyl group (predicted to form a 
hydrogen bond with Asn 382 [6] in NMS) was removed from N-Methylatropine (Fig. 7).  
In comparing the binding affinities of N-Methylatropine and N- Methylhomatropine, it was 
shown experimentally that removing this methylene group reduced binding 90 fold (8). In 
N-Methylacetyltropine, the hydroxylmethyl and benzene ring were removed and the 
binding affinity was further reduced (8). We observed a similar trend in our predictions 
where the calculated relative binding energy (in absolute value) decreased from 28.55 
kcal/mol for N-Methylatropine (pIC50=9.56±0.04) to 21.92 kcal/mol for N-
Methylhomatropine (pIC50=7.61±0.04), and further to 12.63 kcal/mol for N-
Methylacetyltropine (pIC50=5.44±0.04), which correlates well with the change in 
measured binding affinities for these NMS derivatives. It should be noted that the 
calculated binding energies do not include the room temperature effects, or explicit 
entropic terms. 
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Predicted Binding Site for Antagonist 4-DAMP 
The binding site of the antagonist 4-DAMP is located between the TM helices 3, 4, 5, 6, 
and 7. Fig. 11 shows the 4 Å binding site of 4-DAMP, or 4-diphenylacetoxy-N-
methylpiperidine methiodide. The quaternary ammonium head group forms a 3.8Å weak 
salt bridge with Asp 105 [3], which is expected for a quaternary ammonium group. The 
surrounding aromatic residues Tyr 404 [7], Tyr 408 [7], and Tyr 381 [6] interact with the 
ligand head group through cation-π interactions (Fig. 11). The carbonyl group of the ester 
moiety forms a hydrogen bond to Ser 109 (2.9 Å). Ser 109 also forms an inter-helical 
hydrogen bond with Tyr 381 (2.9 Å). The two benzene rings of 4-DAMP and surrounding 
aromatic residues Tyr 106 [3], Trp 157 [4], Trp 378 [6], Phe 197 [5], and Tyr 381 [6] form 
an aromatic network that stabilizes the 4-DAMP binding site. 
 
Predicted Binding Site for Antagonist Quinuclidinyl Benzilate (QNB) 
Fig. 12 shows the residues within the 4 Å binding site of (-)-QNB. The predicted binding 
site of QNB is located between helices 3, 4, 5, 6, and 7. The charged protonated tertiary 
amine group forms a salt bridge with Asp 105 [3] at a distance of 2.7 Å. The hydroxyl 
group of QNB is hydrogen bonded to Asn 382 [6] at a distance of 2.9 Å. The ester moiety 
of QNB is hydrogen bonded (2.9 Å) to Ser 109 [3]. As in 4-DAMP, the QNB benzene ring 
is caged by the surrounding aromatic residues Tyr 106 [3], Trp 157 [4], Trp 378 [6], Phe 
197 [5], and Tyr 381 [6] that stabilize the binding site. 
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Predicted Binding Site for Antagonist Pirenzepine 
Fig. 13 shows the 4 Å binding site of pirenzepine. The pirenzepine binding site involves 
residues from TM helices 3, 4, 5, 6, and 7. The charged protonated tertiary amine group of 
pirenzepine forms a salt bridge (2.9 Å) with Asp 105 [3]. The lactam group of pirenzepine 
forms a hydrogen bond (2.9 Å) with Asn 382 [6]. As in other ligands, the pirenzepine 
benzene ring and the surrounding aromatic residues Tyr 106 [3], Trp 157 [4], Phe 197 [5], 
Trp 378 [6], and Tyr 381 [6] form an aromatic cage that stabilizes the binding site.  
 
Predicted Binding Site for Acetylcholine, the Endogenous Agonist 
The predicted binding site of acetylcholine is located between TM helices 3, 6, and 7 as 
shown in Fig. 14. There is a salt bridge (3.9 Å) between Asp 105 [3] and the quaternary 
ammonium head group of acetylcholine. The head group is also stabilized by the 
surrounding aromatic sidechains Tyr 381 [6], Tyr 404 [7], and Tyr 408 [7] through cation-π 
interactions (Fig. 13). Trp 101 [3] is also in close proximity to the acetylcholine head 
group. The carbonyl group of the ester moiety of acetylcholine is hydrogen bonded to both 
Tyr 381 (2.9 Å) and Ser 109 (2.8 Å). 
  
The Effect on Acetylcholine Binding of Alanine Mutations in M1 
We performed systematic mutation of the residues in the binding site of acetylcholine (all 
residues within 6 Å) to Ala and calculated the change in binding energy, to compare to 
the Ala substitution mutagenesis data on acetylcholine binding affinity. We observed that 
the following residues changed the binding energies by more than 2.5 kcal/mol: Asp 105 
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[3], Tyr 106 [3], Ser 109 [3], Tyr 381 [6], Tyr 404 [7], and Tyr 408 [7].  The Ala 
mutations of these residues significantly reduced acetylcholine binding affinities by 70, 
60, 10, 40, 30, and 30 fold, respectively (8, 10, 11).   
 
Predicted Binding Site for Agonist Oxotremorine-M 
Fig. 15 shows the 4 Å binding site of oxotremorine-M. This agonist binds in a similar 
location as acetylcholine between helices 3, 6 and 7. There is a salt bridge (3.9 Å) between 
Asp 105 [3] and the quaternary ammonium head group of oxotremorine-M. The head 
group is also stabilized by the surrounding aromatic side chains including Tyr 381 [6], Tyr 
404 [7], and Tyr 408 [7] through cation-π interactions (Fig. 14). The carbonyl group of the 
ester moiety of oxotremorine-M is hydrogen bonded to both Tyr 381 [6] and Ser 109 [3], 
with a distance of 2.9 Å.  
 
Predicted Binding Site for Agonist Tetramethylammonium 
The tetramethylammonium ion is also an agonist (pIC50 = 2.9) and binds similarly to the 
acetylcholine head group (Fig. 16). The tetramethylammonium ion is stabilized by both a 
salt bridge (3.6 Å) with Asp 105 [3] and by cation-π interactions with the surrounding 
aromatic residues Tyr 381 [6], Tyr 404 [7], and Tyr 408 [7].  The distances of the cation-π 
interactions are listed in Fig. 15. 
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Nature of Agonist Interaction Compared to the Antagonist Interaction with the M1 
Receptor  
To understand quantitatively how the agonist interacts with the receptor compared to the 
antagonist, we have calculated the interaction energy of all the residues in the binding site 
(within 6Å) with the ligand. The summation of the contribution from each residue on a 
particular TM helix to the interaction energy shows how strongly the ligand interacts with 
that particular TM helix. The results for antagonists with a quaternary ammonium head 
group (NMS and 4-DAMP) are listed in Fig. 17 and Fig. 18. The results for antagonists 
with the basic tertiary amine head group (QNB and pirenzepine) are listed in Fig. 19 and 
Fig. 20. The results for acetylcholine are listed in Fig. 21 and Fig. 22.  Our results 
suggested that the interaction energy of the antagonists with TM 3 and TM 6 are strong, 
followed by TM 7. The Asp 105 [3] salt bridge plays a much more significant role in 
binding the antagonists with a tertiary amine head group than in binding the ones with a 
quaternary ammonium head group.  
 
 
Discussion 
Antagonist Binding: Comparison of NMS Binding Site with Mutagenesis Data 
The effect of Ala mutations for the residues in TM 2, 3, 4, 5, 6 and 7 on the binding 
affinity of NMS (Kd=125 pM) has been well studied experimentally (7, 25). The predicted 
4 Å NMS binding site includes eight of the nine ligand-anchor residues whose Ala 
substitution mutation caused >30-fold reduction in NMS affinity in the scanning 
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mutagenesis experiments. These residues include Asp 105 [3], Tyr 106 [3], Trp 157 [4], 
Tyr 381 [6], Asn 382 [6], Tyr 404 [7], Cys 407 [7], and Tyr 408 [7] (Fig. 9C). The only 
exception is Pro 159 [4], whose Ala substitution mutation caused a 63-fold reduction in 
NMS binding (10), but caused a very small reduction (less than 3%) in calculated binding 
energy.  In the predicted structure, Pro 159 [4] has a secondary effect on NMS binding by 
inducing a bend in TM4 that helps to position Trp 157 [4] at the NMS binding site. When 
Pro159 is mutated to Ala computationally, the bend in the backbone caused by proline is 
kept and the helical structure has not been reoptimized for Ala instead of Pro. This 
substitution may give rise to a different helical structure for TM4. Hence the calculated 
effect on the binding energy due to Ala substitution of Pro 159 is small. However, 
experimentally such a substitution might change the nature of the bend in TM4.  Trp 157 
[4] was implicated to be important in ligand binding in M1. Its Ala substitution mutation 
caused a 123 fold reduction in NMS binding (10), a 132 fold reduction in 4-DAMP binding 
(12), and a 330 fold reduction in QNB binding affinity (10). In the predicted structure we 
found that Trp157 [4] is directly involved in binding of these antagonists.  
 
Placement of TM 4 in the predicted M1 structure is critical to explaining the 
experimental observations on Trp157. The predicted M1 structure is different from the 
rhodopsin-based homology model in the relative translational position of TM4. In the 
MembStruk predicted M1 structure, Trp 157 [4] is located next to Tyr 106 [3] at the 
predicted binding site, whereas in homology models, Trp 157 [4] was placed near the N-
terminal end of TM3, close to Asp 99 [3].  Since the homology models do not directly 
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explain the effect of Trp157 mutation experiments, it was postulated that Trp 157 
might form a putative secondary docking site before ligands enter the main binding site 
(7, 10). However, the MembStruk predicted structure suggests that Trp 157 [4], instead of 
forming a secondary docking site, directly interacts with the antagonists at the central 
binding site through aromatic-aromatic interactions. Our results provide a structure basis 
for explaining the strong effects of these mutations on ligand binding.  The step of the 
Membstruk procedure that optimizes the relative translation of the helices by aligning the 
hydrophobic centers (the position of the maximum hydrophobicity as shown in Fig. 5) for 
each helix to a plane, is essential in determining the ligand binding sites as shown by 
Trp157 [4].  
 
Common Features of Antagonist Binding Sites 
Antagonists with a Charged Quaternary Ammonium Head Group 
Many M1 antagonists, including NMS and 4-DAMP (Ki = 900 pM), have a charged 
quaternary ammonium head group. In the binding sites of both  NMS and 4-DAMP, the 
positively charged quaternary ammonium head group of the ligand is stabilized by the 
negatively charged Asp 105 of TM3 and the surrounding tyrosine residues (Tyr 381, Tyr 
404, Tyr 408) of TM 6 and 7, primarily though cation-π interactions.   
 
Binding Site of Charged Tertiary Amine Group in Antagonists  
Antagonists QNB (Kd=16 pM) and pirenzepine (Ki = 4.4 nM) have a tertiary amine head 
group. The interaction energy calculations for each residue in the binding site suggested 
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that Asp 105 [3] plays a much more significant role in binding antagonists with a 
charged tertiary amine head group than the ones with a quaternary ammonium head group. 
We performed quantum mechanical calculations at the Hartree-Fock level with 6-31G** 
basis set. The charge density at the atom centers suggested that while there is an extensive 
delocalization of positive charges onto the surrounding methyl groups in quaternary 
ammonium, the positive charges are more concentrated on the protonated hydrogen in a 
tertiary amine, suggesting the relative importance of a salt bridge in binding the tertiary 
antagonists. In the predicted structure, there is a salt bridge between the terminal oxygens 
of the carboxylate group of Asp105 and the QNB amine group with a distance of 2.7 Å, 
and between Asp 105 and pirenzepine with a distance of 2.9 Å (Fig. 11 and Fig. 12).  This 
explains well the experimental results, where the Ala mutation of Asp 105 caused a 6000 
fold reduction in QNB binding, while it only caused a 100 fold reduction in NMS binding 
(11).  In the latter case, the aromatic residues surrounding the quaternary ammonium head 
group play a more significant role in NMS binding through cation-π interactions. We 
predict that the Asp 105 to Ala mutation will also have a significant effect on pirenzepine 
binding. 
 
Due to the hydrophobic nature of the antagonist binding sites, we conducted quantum 
mechanical geometry optimization (with B3LYP/6-31g** basis set) to evaluate the 
likelihood of proton transfer from QNB to Asp 105 [3] using their docked geometry as the 
starting structure (Fig. 23). The results suggest that in the environment of vacuum 
(dielectric constant =1), cyclohexane (dielectric constant=2.0), and benzene (dielectric 
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constant = 2.3), the proton will transfer from the QNB tertiary amine to the carboxylate 
group of Asp 105 [3], whereas in methanol (dielectric constant = 33.6) and in water 
(dielectric constant = 80.4), the proton will remain on QNB, forming a salt bridge with Asp 
105 [3].  The QNB head group is surrounded by aromatic residues, which might be 
mimicked by a benzene rich environment. In addition, benzene has a dielectric constant of 
2.3, which is very similar to the averaged dielectric constant of amino acids (average value 
= 2.5). Therefore, our results suggest that proton transfer might occur upon QNB binding. 
Antagonists with a quaternary ammonium head group lack the proton that can be 
transferred to Asp 105 [3] upon binding, which also explains the relative importance of Asp 
105 [3] in tertiary antagonist binding that we mentioned earlier.  
  
The Aromatic Cage that Stabilizes the Ligand-Receptor Complex 
It has been shown experimentally that the benzene ring at the end of the NMS tropic acid 
side chain was essential for high-affinity NMS binding (8). The predicted structure enabled 
us to examine, at the atomic level, how this benzene ring is stabilized by the surrounding 
aromatic residues including Tyr 106 [3], Trp 157 [4], and Trp 378 [6] (Fig 9C). As we 
described above, the Ala substitution mutations of both Tyr 106 [3] and Trp 157 [4] 
significantly reduced NMS binding. In a separate study (12) where Trp 378 [6] was 
mutated to Ala, the NMS binding was reduced 115 fold, while its Phe mutation had 
negligible effect (1.8 fold). This confirmed the importance of the aromatic nature of this 
residue. In the predicted NMS binding site, the NMS benzene ring, Tyr 106 [3], Trp 157 
[4], Trp 378 [6], and additional aromatic residues including Phe 197 [5] and TM6 Tyr 381 
[6], form an aromatic cage that contributes to the stability of the receptor-NMS complex. 
  
29 
The aromatic-aromatic interactions observed in our predicted binding site are very 
similar to the ones commonly observed in many protein crystal structures, where the 
positively charged hydrogen atoms at one aromatic ring lie closely to the negatively 
charged carbon atoms at another aromatic ring, forming favorable edge-face or parallel-
displaced interactions (26, 27).  
 
The predicted binding sites of QNB and 4-DAMP show that similar aromatic-aromatic 
interactions are also critical for QNB and 4-DAMP binding, both of which contain two 
benzene rings that interact with the M1 aromatic residues. The available mutagenesis 
results and the effect on 4-DAMP and QNB binding confirmed the importance of these 
aromatic residues in the binding site.  The known mutations include Trp 378 [6] to Ala 
which reduced 4-DAMP binding 288.2 fold (12), Trp 157 [4] to Phe mutation which 
reduced 4-DAMP binding 131.9 fold (12), Trp 157 [4] to Ala mutation which reduced 
QNB binding 330 fold (10), and Tyr 106 [3] to Ala mutation which reduced QNB binding 
31 fold (11). All these residues mentioned above are within the 4 Å binding sites of 4-
DAMP and QNB. We predict that the mutations of these aromatic residues should affect 
the binding affinity of pirenzepine as well.  
 
Role of Aromatic Residues on EC2 Loop and Extracellular End of TM Helices  
From examining the binding site of 4-DAMP where its terminal two benzene rings are 
solely responsible for its high affinity binding at the opposite side of its quaternary 
ammonium group, we observed that Trp 164 near the extracellular end of TM4, Tyr 179 on 
the second extracellular (EC2) loop, and Phe 391 near the extracellular end of TM 6 also 
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participate in the aromatic network, extended through the upper benzene ring of the 
antagonist 4-DAMP (Fig. 24) with Trp 164 [4] and Phe 391 [6] within 5 Å to 4-DAMP. 
The extended aromatic network explains why the addition of an extra benzene ring at the 
end of the antagonist increased ligand binding affinities significantly (8).  
 
In the QNB docked structure, the above aromatic residues do not lie immediately next to 
QNB.  In the bovine rhodopsin crystal structure, the EC2 loop forms the roof of the binding 
site.  We describe the EC2 conformation in bovine rhodopsin as in its closed form. We 
conducted additional annealed dynamics to further optimize the EC2 loop, allowing the 
residues of the EC2 loop, the terminal 4 residues at the extra-cellular end of TM4 and TM5, 
and the ligand to move, while keeping all other residues fixed. We observed that the EC2 
loop moved closer to the binding site and curved similarly to the EC2 loop in the bovine 
rhodopsin crystal structure.  Fig. 25 compares the original predicted structure (with an open 
EC2 loop built by the MODELLER homology modeling program (36)) and the EC2 closed 
structure. The closure of EC2 loop brought Tyr 179 [EC2] and Trp 164 [4] to within 5 Å of 
QNB, where these aromatic residues participate in the aromatic network that contributes to 
stabilizing the QNB binding site. Further mutagenesis to study the effect on QNB and 4-
DAMP binding by the Ala mutations of these residues, especially Trp 164 [4], which is 
also conserved across M1-M5, will help to confirm the role of these aromatic residues in 
antagonist binding.  
 
The Role of Asn 382 of TM6 in Antagonists Binding 
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In the predicted NMS binding site, Asn 382 [6] forms a hydrogen bond with the 
hydroxylmethyl group in the tropic acid side chain of NMS (Fig. 9C). The Ala substitution 
mutation of Asn 382 reduced NMS binding by more than 1000 fold, indicating its 
importance in NMS binding.  
 
In the pirenzepine binding site (Fig. 13), Asn 382 [6] forms a hydrogen bond with the 
lactam group of pirenzepine. This hydrogen bond and the salt bridge with Asp 105 [3] 
should be important in anchoring pirenzepine from its opposite ends in M1. The Asn 382 
[6] to Ala mutation had strong effects on pirenzepine binding, reducing its binding affinity 
by 7700 fold in M1 (41) and by 842 fold in M3 (42). Our results correspond well to these 
mutagenesis data.  
 
In the QNB binding site (Fig. 12), Asn 382 [6] forms a hydrogen bond with the hydroxy 
group of QNB.  The Ala mutation of Asn 382 [6] caused a 90 fold reduction in QNB 
binding.  QNB has two terminal aromatic rings while NMS has only one aromatic ring that 
could interact with the aromatic residues in the binding site.  This explains why the Ala 
substitution mutation of Asn 382 [6] had a stronger effect on NMS binding (reducing it by 
more than 1000 fold) than on QNB binding affinity (reducing it by 90 fold).  
 
The Binding Site of the Ester Moiety of Antagonists 
For all the antagonists except for pirenzepine, the carbonyl oxygen of their ester moiety is 
hydrogen-bonded to the hydroxy group of Ser 109 [3] at the predicted binding sites.  
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However, calculation of the interaction energy of the ligand with the residues in the 
binding site (within 5Å) suggested that this is a relatively weak hydrogen bond. For 
example, the calculated non-bond interaction energy is -1.3 kcal/mol between NMS and 
Ser 109 [3] and -2.0 kcal/mol between QNB and Ser109 [3]. This is a weak interaction 
compared to the interaction energy of -6.8 kcal/mol between NMS and Asn 382 [6], which 
explains why the Ala mutation of Ser 109 [3] did not have a significant effect on NMS and 
QNB binding (11). Because an ester is a relatively weak hydrogen bond acceptor (28), we 
suspect that anchoring the two ends of an antagonist might be sufficient for its high affinity 
binding. In fact, in the crystal structure complex of carbamylcholine binding to 
Acetylcholine-binding Protein (21), a water-soluble homolog of the ligand binding domain 
of nicotinic acetylcholine receptors, there is no hydrogen bond between the receptor and the 
carbamylcholine ester moiety (Fig. 26).   This view is also supported by other results (8). 
Ward 1999 measured the binding affinities of the M1 antagonists diphenylacetyltropine and 
benztropine; both are atropine derivatives (NMS variants) where the ester carbonyl group is 
present in diphenylacetyltropine but removed in benztropine. Ward showed that removing 
this carbonyl group actually increased the binding affinity of diphenylacetyltropine by 20 
fold (8). 
 
Agonist Binding Site in the M1 Receptor 
The Binding Site of the Charged Quaternary Ammonium Head Group: Comparison with 
the Nicotinic Acetylcholine Binding Site 
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Acetylcholine is the endogenous agonist for the muscarinic acetylcholine receptors and 
has a binding affinity of 17 µM for M1.  Oxotremorine-M is an agonist with a binding 
affinity of 9.9 µM (12). In the predicted binding sites (as shown in Fig. 14 and Fig. 15), the 
quaternary ammonium head group of both acetylcholine and oxotremorine-M are stabilized 
by the negatively charged Asp 105 [3] as well as the surrounding aromatic residues Tyr 381 
[6], Tyr 404 [7], and Tyr 408 [7] through cation-π interactions. These residues were shown 
experimentally to be important in acetylcholine binding. For example, acetylcholine 
mustard, an analogue of acetylcholine in which its headgroup was replaced by a chemical 
reactive aziridinium moiety, selectively labeled Asp 105 (29). In addition, the Ala 
substitution mutations of Tyr 381 [6], Tyr 404 [7], and Tyr 408 [7] each reduced 
acetylcholine binding affinity by about 30 fold (8, 10). Note that the distances between the 
acetylcholine head group and the surrounding aromatic rings (Fig. 14) are very similar to 
the ones observed in the crystal structure (21) of the nicotine acetylcholine receptor binding 
site (Fig. 26).  Similar distances between the quaternary ammonium group and the phenyl 
rings were also observed in the binding sites of antagonists (NMS and 4-DAMP) that have 
a quaternary ammonium head group (Fig. 9C and Fig. 11).   
 
Binding site of the Ester Moiety in Agonists Leads to Breaking the Interhelical Hydrogen 
Bond between TM 3 and TM 6  
In the predicted binding site in M1, the ester moieties of acetylcholine and oxotremorine-M 
are hydrogen bonded to both Tyr 381 [6] and Ser 109 [3] (Fig. 14 and Fig. 15).  The Ala 
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mutation of Tyr 381 [6] and Ser 109 [3] reduced acetylcholine binding by 30 and 10 fold, 
respectively (8, 11). In addition, it has been shown (8) that the hydroxy group of Tyr 381 
[6] is important in acetylcholine binding in M1 because the Phe mutation of this residue 
significantly reduced acetylcholine binding in a magnitude similar to an Ala mutation 
(while having negligible effects on NMS binding). In M2, the equivalent mutation (Tyr403 
to Phe) also had a differential effect on agonist and antagonist binding. This mutation 
reduced the NMS and QNB affinities to 2.5 and 1.7 fold, respectively, but reduced 
acetylcholine affinity 280 fold (47). To test this differential effect on agonists and 
antagonists binding in the predicted M1 structure, we mutated Tyr 381 to Phe at the NMS, 
QNB, and acetylcholine binding sites and recalculated their binding energy. We observed a 
small decrease (6%) in binding energy for NMS and no change in binding energy for QNB. 
However, there is a significant decrease (44%) in binding energy for acetylcholine, which 
parallels the experimental data.   
In the predicted structure we found that there is an interhelical hydrogen bond (2.9 Å) 
between Tyr 381 [6] and Ser 109 [3]. When the agonists (acetylcholine and oxotremorine-
M) bind to this site, they break this interhelical hydrogen bond by wedging in between and 
compensate by making a hydrogen bond between the ester moiety and the Tyr381 [6] (Fig. 
27). This interhelical hydrogen bond is not broken when an antagonist binds to this site (Fig 
27).  This breaking of interhelical hydrogen bond on agonist binding might contribute to 
receptor activation by weakening the intra-molecular contacts between TM 3 and TM 6. 
The Internal Torsional Conformation of the Docked Aceytlcholine :  
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The docked conformation of acetylcholine at the predicted binding site is a gauche 
conformation with an NCCO torsion angle of 59°, and it is the lowest energy conformation 
after the extensive internal conformational sampling of the Hierdock simulated annealing 
procedures used for predicting the binding site. The predicted torsion angle corresponds 
extremely well to the experimentally observed value (an NCCO torsion angle of 60°) in a 
transferred NOE NMR study of the acetylcholine analogue S-(+)-acetyl-β-methyl choline 
bound to the ground state of the M2 receptor (30). The same experiment also suggested that 
the conformation of bound acetylcholine in the activated state of the receptor is trans with 
an NCCO torsion angle of 132°. This result, together with the rotational orientation of TM5 
and the inter-helical contacts involving Leu 116 [3], Phe 374 [6], and Asn 414 [7] that 
selectively stabilize the receptor ground state (Fig. 2D), suggest that our predicted structure 
might correspond to the inactive state of the receptor.  
 
The Role of TM 5 in Agonist and Antagonist Binding  
In the rotational optimization of the helical orientations (discussed in the Methods section 
and shown in Fig. 39) there are two possible orientations found for TM5. They are 0 
degrees and 90 degrees. In the current structure discussed, we have taken the 0 degrees 
rotation structure for TM5 because it is the orientation that has the lowest energy in 
rotational energy scans for TM 5.  In this structure, TM5 is at the farthest end of the 
binding site with Ala 193 [5] pointing towards the binding site. This rotational orientation 
of TM5 corresponds well to the experimental results reported by Allman 2000, which, out 
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of the mutations of Ile 188 [5] through Ala 196 [5], only that of Ala 193 [5] to Cys 
reduced the binding affinity by 3.6 fold (9). In addition, the sulfhydryl reagent N-trimethyl-
2-aminoethyl methanethiosulfonate reacted selectively with Ala 193 [5] when it was 
mutated to Cys and the residues on both sides of Ala 193: Phe 190 [5] → Cys and Thr 192 
[5] → Cys (9).  Allman et al 2000 also proposed that an agonist induced rotation of TM5 
might accompany the receptor activation (9). Interestingly, we observed a second energy 
minimum in TM5 360° energy rotational scans at the orientation where TM5 is rotated 90° 
clockwise looking from the extracellular side. In this orientation, Thr 192 [5] points toward 
the binding site, which is exactly the TM5 orientation of the active state suggested by 
Allman (9). 
 
Role of Trp 157 [4] in Agonist Binding 
Trp 157 [4], the residue whose Ala substitution significantly affected antagonist binding, 
also reduced acetylcholine binding 90 fold. In the predicted structure, Trp 157 [4] is within 
a 5.5 Å distance to the bound acetylcholine (Fig. 14) and is a part of the aromatic network. 
The mutation of Trp 157 [4] might affect the packing of the binding site residues including 
its immediate neighbor Tyr 106 [3] that interacts with acetylcholine. As we discussed 
earlier, different patches of residues of TM5 affected agonist or antagonist binding.  At the 
TM5 rotational orientation of 90 degrees presumably corresponding to the orientation at the 
activated state, Thr 189 [5], Thr 192 [5] and Ala 196 [5] that selectively affected 
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acetylcholine binding are located immediately next to Trp 157 [4], suggesting a possible 
role of Trp 157 [4] in acetylcholine binding in the active state of the receptor. 
  
Comparison of Agonist and Antagonist Binding Sites 
By comparing the structures of M1 agonists and antagonists, we notice that 
acetylcholine, oxotremorine-M, and many other agonists can be superimposed to the 
antagonist NMS and 4-DAMP because they share the quaternary ammonium head group 
and the ester moiety. However, acetylcholine lacks the two benzene rings in 4-DAMP and 
the hydroxylmethyl and benzene ring at the end of the NMS tropic acid side chain that can 
form aromatic-aromatic interactions or hydrogen bonds with the binding site residues of 
TM 3, 4, 5, and 6. This is probably how antagonists keep the receptors from activation by 
locking these TM helices in place, while agonists allow their conformational flexibility 
required for activation. This view was suggested earlier (31). The antagonist nature of 
benzilylcholine (8) also supported this view. In benzilylcholine, two benzene rings and a 
hydroxy group (as seen in QNB) replaces the terminal methyl group (next to the ester) of 
acetylcholine, which switches it from an agonist to an antagonist. Fig. 28 summarizes the 
binding regions of antagonists and agonists used in this study. The binding regions for 
agonists and antagonists overlap between TM 3, 6, 7 while the antagonists binding region 
extends to TM 4 and TM 5.  
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Comparison of the Calculated Ligand Binding Energies and Experimental 
Dissociation Constants 
We calculated the binding energies of all the 10 ligands used in this study and 
compared the results with their experimental dissociation constants –log (Kd), -log (Ki), or 
–log (IC50). The molecules selected represent a diverse set of ligands, including both 
agonists and antagonists. Fig. 28 show that the calculated relative binding energies 
correlate well with experimentally measured binding affinities. The R square values for 
antagonists, agonists, and all ligands are 0.84. It should be noted that the calculated binding 
energies do not include the room temperature effects, or explicit entropic terms.  
 
Conclusion 
 
The predicted 3D structure of the human M1 receptor, and the predicted binding 
sites of 10 agonists and antagonists, both based on first principles, provide a sound 
structural basis for the measured ligand binding affinities and mutagenesis data. The 
calculated relative binding energies also correlate well with measured binding affinities. 
In addition, the predicted binding sites provide a structural basis to better explain the 
large reduction in ligand binding affinity and signaling efficacy by mutations of Trp 157 
and Pro 159 of TM 4 for which prior models differed. The predicted structure explains 
the differential effect of Tyr 381 [6] to Phe mutation on agonist and antagonist binding, 
as well as the stronger reduction in binding affinity by Asp 105 [3] to Ala mutation for 
antagonists with a tertiary amine head group. It also explains why the Asn 382 [6] to Ala 
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mutation affected NMS more than QNB. The predicted structure shows the importance 
of binding site aromatic residues and illustrates, in atomic detail, the cation-π interactions 
and aromatic-aromatic interactions critical to ligand binding in M1. Several new mutation 
candidates were suggested, including Trp 164 at the extracellular end of TM 4 (for its 
effect on the binding affinities for antagonists with two terminal benzene rings) and 
additional aromatic residues (Phe 197 [5], Tyr 179 [EC2], and Phe 391 [6]) that are part 
of the aromatic network stabilizing the antagonist binding sites. The detailed structure of 
M1 and its binding sites provides a basis for structure-based drug design. This study and 
several successful recent studies in other GPCRs justify carrying out similar studies to 
predict the structures and ligand binding of the other four muscarinic receptor subtypes, 
which should, in turn, improve our understanding of the origins of subtype specificities in 
muscarinic receptors. 
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C h a p t e r  3  
COMPUTATIONAL METHODS 
 
 
 
Structure Prediction of GPCR: The MembStruk Method 
 
The Membstruk method (version 4.0) was used to predict the M1 structure with 
each step listed in the following section. A detailed description of the Membstruk method 
(version 3.5) used here has been published (14). In Membstruk 4.0, we have made 
advances in generating a large number of well packed conformations with additional 
criteria including total all-atom forcefield energy, number of interhelical hydrogen bonds 
and salt bridges in determining the rotational orientation of the transmembrane (TM) 
regions. All energy and force evaluations used the DREIDING force field (32) and 
CHARMM22 charges (33) for the protein. In this chapter we only detail the advances in 
the MembStruk 4.0 method from its previously published version MembStruk 3.5 (14). The 
various steps as applied to prediction of the M1 structure are: 
 
TM Prediction (TM2ndS).  
We predicted each TM region by using alignments of 51 sequences that have sequence 
similarities to M1 varying from 99% to 24% using the BLAST search. The alignment 
includes 45 M1-M5 sequences from various species and 4 sequences from histamine 
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receptors and 2 from octopamine receptors. M1-M5 receptors have more than 40% 
overall sequence identity and 60% sequence identity in the TM regions. Histamine and 
octopamine receptors were identified by BLAST to have the highest homology to M1 
outside of the muscarinic receptor family. Histamine and M1 receptors have 29% overall 
sequence identity and 37% sequence identity in the TM regions, while octopamine and M1 
receptor have 24% overall sequence identity and 35% sequence identity in the TM regions. 
By including sequences with lower homology, we improved the identification of the 
boundary between TM 2 and 3 (the EC1 loop), which is highly hydrophobic in all M1-M5. 
Then, we calculated the average hydrophobicity for every residue position over all the 
sequences in the multiple sequence alignment and averaged over window sizes of 12 to 20 
residues. The baseline for this profile served as the threshold value for determining the TM 
regions (Fig 1).  Because it is possible that the actual length of the helix could extend past 
the membrane surface, we carried out an additional capping step as described in Trabanino 
2004 (14), based on properties of known helix breaker residues, to further refine where 
each predicted TM region ends. 
  
Optimization of the Translational Orientation of the Helices. 
TM2ndS also predicted the position of maximum hydrophobicity called the “hydrophobic 
center” for each helix. The seven canonical α-helices were built with the predicted TM 
sequences and the helical axes were positioned based on the 7.5-Å density map of frog 
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rhodopsin (34). Relative translational orientation of the helices was optimized by fitting 
the hydrophobic centers of the TM helices to a common plane.  
Optimization of Helical Bends and Kinks  
We constructed canonical helices for the predicted TM segments and optimized the 
individual helices using energy minimization followed by Cartesian molecular dynamics at 
300K for 500 ps.  This procedure optimized the bends and kinks in each helix.  
 
Optimization of Rotational Orientation of the Helices  
Step 1 Hydrophobic moment: The rotational orientation of the helices was determined 
according to the hydrophobic moment of the middle portion of each helix (about its 
hydrophobic center) to point the moment of each helix towards the lipids.  
Step 2 Monte Carlo optimization (RotMin): In this procedure, each of the seven TMs was 
optimized through a range of rotations one at a time while the other six helices were re-
optimized in response. After each rotation, the side-chain positions of all residues for all 
seven helices in the TM region were optimized using SCWRL (35). The potential energy of 
the rotated helix was then minimized in the field of all other helices. This procedure was 
carried out for a grid of rotation angles (every 5° for a range of ±25°) to determine the 
optimum rotation for each helix. Once we rotated the helix to its optimum rotation, we kept 
it fixed while allowing each of the other six helices to be rotated and optimized.  The 
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optimization of these six helices was done iteratively until the entire grid of rotation 
angles was searched. This method optimized the rotations locally. 
Step 3 Energy Scan: This step is the recent refinement from MembStruk 3.5 and is included 
only in Membstruk 4.0. We took the structure generated from step 2 as the initial structure 
and rotated each individual helix while fixing the other six helices. We rotated the helix in 
5° intervals for 360° and calculated the energy of the rotated helix after reassigning the side 
chain conformation (with SCRWL) and minimizing the energy of the entire protein (35). 
We also calculated the number of interhelical hydrogen bonds and salt bridges to identify 
favorable inter-helical interactions. Step 3 allowed us to identify additional low-energy 
rotation orientations for each helix assuming Step 1 and 2 predicted good rotational 
orientations for other helices.  We conducted energy scans iteratively until we reached a 
structure where all the seven helices are within 15° of its lowest energy minimum in 360° 
scans. The scanning results are shown in Fig. 30-43 where the 0° rotational orientation 
represents the final conformation of each helix. Because Step 2 and 3 are more important 
for optimizing helix 3, which is less amphipathic due to its center location, we docked 
ligands to both the 0° conformation and the conformation of its second lowest energy 
minimum where TM3 was rotated 20° clockwise from its lowest minimum (at 0°). These 
two structures are very similar. While most ligands dock very well to the 0° structure, the 
antagonist NMS and its derivatives, having bigger head groups than acetylcholine and other 
ligands, do not fit as well in the 0° structure as they fit in the 20° structure. Therefore, the 
20° structure was selected and reported here.  
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Loop Building and Optimization of the Final Model  
The loops were added to the helices using the loop builder in the MODELER homology 
modeling program (36). We omitted modeling the amino terminal before TM1 and 
carboxyl terminal region after TM7. The third intracellular loop between TM 5 and TM 6 
was truncated to 25 residues with the residues 225 to 353 deleted (the dLoop mutation) 
because such large loops are quite flexible, leading to a multiplicity of conformations with 
similar energies. It has been shown experimentally that the d-Loop mutation had little 
effect on ligand-binding affinities (37) and should have little effect on the structure of the 
TM region. Disulfide linkages were created between Cys 98 [TM 3] – Cys 178 [EC2 loop]. 
We then performed side chain replacement with SCWRL and optimized the final structure 
by using conjugate gradient minimization of all atoms in the structure.   
 
Functional Prediction of GPCRs: The HierDock Protocol  
The ligands used in this study were described with the DREIDING FF and 
Gasteiger charges (38). The HierDock 2.0 procedure (13) was used. The ligand-screening 
protocol followed a hierarchical strategy for examining ligand-binding conformations and 
calculating their binding energies.  This method has been tested for various GPCRs (13-20), 
outer membrane protein A (39), and globular proteins (40-43). The HierDock protocol is 
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described in detail in these references. In brief, the parameters used for ligand binding 
site predictions in M1 are as follows: 
 
Scanning the Entire Receptor for Binding Sites  
The void space in the entire receptor was mapped using the SPHGEN DOCK 4.0 utility 
(29). The entire set of spheres was divided into 27 regions for scanning and locating the 
binding site of ligands without any prior bias.  Five representative ligands including 
NMS, QNB, 4-DAMP, acetylcholine, and tetramethylammonium were used for scanning.  
In each of these regions we carried out DOCK 4.0 to generate and score 500 
conformations, of which 50 (10%) were selected using a buried surface area cutoff of 
85% and energy scoring from DOCK 4.0. In Step 2, the 50 best conformations selected 
were subjected to all-atom minimization keeping the protein fixed but the ligand 
movable.  The 5 best scoring conformations based on the potential energy of the ligand in 
the protein were selected.  We then examined which boxes contained these top 5 hits and 
selected the best boxes based on results from all the ligands. We merged the spheres in 
the top two scoring boxes as the putative binding region for the next step (Fig. 8).?
 
Optimizing the Binding Sites  
Once the plausible binding regions were determined, we docked all the ligands shown in 
Fig. 7 into the putative binding region using the HierDock 2.0 protocol. The best 5 bound 
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structures for each ligand/M1 receptor complexes were chosen.  We then optimized 
this structure using the SCREAM side chain replacement program (Kam, Vaidehi, and 
Goddard, unpublished) to reassign side chains for the residues within 4 Å of the ligand.  
Because the receptor structure is kept fixed in HierDock, we performed simulated 
annealing dynamics to optimize the binding sites, allowing both the receptor side chains 
and the ligands to move. Specifically, we ran annealed dynamics for a total of 120 ps 
cycling between 300K and 700K for 300 cycles for all docked ligands, allowing the 
ligands and the side chain atoms within 5Å from the ligands to move freely while 
keeping the main chain atoms fixed. The ligand-receptor complexes of N-
Methylhomatropine and N-Methylacetyltropine were derived by matching the ligands to 
the optimized N-Methylatropine / M1 complex conformation.  
Binding Energy Calculation   
We calculated the binding energy (BE) of each ligand using the equation BE = PE (ligand 
in protein) – PE (ligand in solvent) as the difference between the potential energy (PE) of 
the ligand in the protein and the potential energy of the ligand in water. The energy of the 
ligand in water was calculated by using DREIDING FF and the surface Generalized Born 
Continuum solvation method (45).  
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Fig. 1 (A) The side view of the predicted M1 structure (B) The top view of
the predicted M1 structure.
A B
TM1 TM5
TM1
TM5
TM4
TM6TM7
TM2
TM3
TM4
 
7.7
8.4
11.0
2.8
2.8
 A B C
D E F
W105
(4)
TM3
TM2
N43 (1)
D71
(2)
N414(7)
L116(3)
F374(6)
W405(7)
T31
(1)
T192(5)
A160(4)
Fig. 2 Illustration of the details of the predicted M1 structure. The numbers
shown in parentheses are the TM helix to which the residue belongs.
D122(3) R365(6)
R210(5)
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Fig. 3 The inter-helical hydrogen bonds observed at the M1 binding sites.
The numbers shown in parentheses are the TM helix to which the
residue belongs.
T391(6)
S109(3)
Y404(7)
Y408(7)
D105(3)
Y381(6)
2.9
2.9
2.9
 
       
 
    H1     H2   H3          H4     H5                                               H6  H7 
Fig. 4 The hydrophobicity profile from TM2ndS for M1 averaged over 
window sizes of 12 to 20 residues. 51 sequences are used in the 
alignment as described in the methods. 
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Fig. 5 The predicted TM regions and the hydrophobic centers (underlined)
of each helix. The length of each region is also listed. The third
intracellular loop between TM 5 and TM 6 was truncated to 25 residues
with the residues 225 to 353 deleted. It corresponds to the dLoop
mutation structure that was shown experimentally to have little effect on
ligand binding (37).
N Terminal (22) MNTSAPPAVSPNITVLAPGKGP
TM 1 (29) WQVAFIGITTGLLSLATVTGNLLVLISFK
IC 1  (6) VNTELK
TM 2 (31) TVNNYFLLSLACADLIIGTFSMNLYTTYLLM
EC 1 (6) GHWALG
TM 3 (28) TLACDLWLALDYVASNASVMNLLLISFD
IC 2 (21) RYFSVTRPLSYRAKRTPRRAA
TM 4 (23) LMIGLAWLVSFVLWAPAILFWQY
EC 2 (16) LVGERTVLAGQCYIQF
TM 5 (28) LSQPIITFGTAMAAFYLPVTVMCTLYWR
IC 3 (25) IYRETENRARELAATFSLVKEKKAA
TM 6 (28) RTLSAILLAFILTWTPYNIMVLVSTFCK
EC 3 (5) DCVPE
TM 7 (21) TLWELGYWLCYVNSTINPMCY
C Terminal (43) ALCNKAFRDTFRLLLLCWDKRRWRKIPKRPGSVHRTPSRQC
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Tetramethyl-
ammonium Acetylcholine 
Oxotremorine-M 
4-DAMP 
S-(-)-N-methyl-
scopolamine (NMS) 
N-methyl- 
atropine 
N-methyl-
homatropine 
N-methyl-
acetyltropine 
(-)-Quinuclidinyl 
benzilate (QNB) Pirenzepine 
Fig. 7 The 10 ligands used in this study which include (1) agonists (in bold): 
tetramethylammonium, acetylcholine, and oxotremorine-M (2) antagonists with 
a tertiary amine head group: QNB and pirenzepine (3) and antagonists with a 
quaternary ammonium head group: 4-DAMP, NMS, N-Methylatropine, N-
Methylhomatropine (4) unknown: N-Methylacetyltropine (in bold), which binds 
similarly to agonists. The biological active S-(-)-enantiomer of NMS and other 
atropine derivatives are used. 
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Fig. 9 (A) The side view of antagonist NMS binding to M1 (B) The top view
of NMS binding to M1 (C) The 4 Å binding site of NMS. The numbers
shown in parentheses are the TM helix to which the residue belongs.
Distances of the important interactions between NMS and M1 binding site
residues are highlighted.
W101(3)
D105(3)
Y408
(7)
Y404(7)
W157(4)
Y106(3)
F197(5)
N382(6)
A193(5)
A106(5)
S109(3)
W378(6)
V385(6)
Y381(6)
C407(7)
A
B
C
2.9
2.9
2.92.93.5
4.5
4.3
5.0
TM1 TM5
TM1 TM5
TM3
 
Box 2 Box 23
Fig. 8 The top two boxes where the ligands docked the best
to. Asp 105 (3), which is located in box 2, is also shown.
TM 7
TM 1
TM 6
TM 5
TM 4
TM 2
TM 3
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Fig. 11 The 4 Å binding site of antagonist 4-DAMP. The numbers shown
in parentheses are the TM helix to which the residue belongs.
C407(7)
Y408(7)
Y404(7)
W101(3) D105(3)
Y106(3)
W157(4)
W378(6)
A193(5)
Y381(6)
V385(6)
N382(6)
F197(5)
S109(3)
T189(5)
4.6
5.0
5.0
3.8
 
Fig. 10 (A) The 4 Å binding
site of N-Methylatropine (B)
N-Methylhomatropine (C) N-
Methylacetyltropine. The
hydrogen bond distances
between Asn 382 and the
ligands are highlighted.
A
B
C
2.9
3.6
N382
N382
N382
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Fig. 12 The 4 Å binding site of antagonist QNB. The numbers
shown in parentheses are the TM helix to which the residue
belongs.
N382(6)
Y408(7)
W101(3)
Y404(7)
D105(3)
W157(4)
Y106(3)
A193(5)
A196(5)
F197(5)
S109(3)
C407(7)
Y381(6)
W378(6)
V385(6) T391(6)
2.9
2.7
2.9
2.9
2.9
2.9
2.9
 
Fig. 13 The 4 Å binding site of antagonist pirenzepine. The
numbers shown in parentheses are the TM helix to which the
residue belongs.
2.9
2.9
C407(7)
Y404(7)
Y408(7)
W101(3)
D105(3)
S109(3)
Y106(3)
W157(4)
A193(5)
A196(5)
F197(5)
Y381(6) V385(6)
W378(6)
T391(6)
N382(6) L386(6)
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Fig. 14 The 4 Å binding site of agonist acetylcholine. The numbers shown in
parentheses are the TM helix to which the residue belongs. Trp157 and Leu
102, which are within the 5.5 Å distance to acetylcholine, are also shown. Thr
391 is not within the acetylcholine binding site. We included Thr 391 in Fig. 10
to illustrate its inter-helical hydrogen bond with Tyr 404.
C407(7)
Y404(7)
Y408(7)
W101(3)
W157(4)
F197(5)
N382(6)
D105(3)
W378(6)
S109(3)
Y381(6)
V385(6)
T391(6)
L102(3)
2.8
2.9
2.8
2.9
4.9
5.0
3.9
4.6
Y106(3)
 
Fig. 15 The 4 Å binding site of agonist oxotremorine-M. The
numbers shown in parentheses are the TM helix to which the
residue belongs. Trp157, which is within 5 Å distance to
oxotremorine-M, is also shown.
C407(7)
Y404(7)
Y408(7)
W101(3)
W157(4)
F197(5)
N382(6)
D105(3)
W378(6)
S109(3)
Y381(6)
V385(6)
2.9
2.9
4.6
5.0
3.9
4.9
Y106(3)
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Fig. 16 The 4 Å binding site of agonist tetra-methylammonium.
The numbers shown in parentheses are the TM helix to which the
residue belongs.
Y404(7)
Y381(6)
C407(7)V385(6)
Y408(7)
W101(3)
D105(3)
5.0
4.7
4.7
3.6
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Fig. 24 The extensive aromatic network at the 4-DAMP binding site.
Y381(6) Y378(6)
F197(5)
F391(6)
W164(4)
W157(4)
Y106(3)
Y179(EC2)
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Fig. 26 Acetylcholine binding to the nicotinic acetylcholine
receptor. The cation-π interaction distances that stabilize the
acetylcholine head group are highlighted.
4.7
4.9
4.9
4.9
 
Fig. 25 The structure in purple has a closed EC 2 loop after further annealing
dynamics, allowing the EC 2 residues, the ligand, and residues at the extra-
cellular end of TM4 and TM5 to move, while keeping all the other residues
fixed. The original structure (open loop) is shown in cyan. The closure of the
EC2 loop brought Tyr 179 at the EC 2 loop and Trp 164 at the extra-cellular
end of TM4 to within 5 Å of QNB.  These aromatic residues extend the
aromatic cage at the QNB binding site described earlier.
Y179
(EC2)
W164
(4)
QNB
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Y381 (6)
S109 (3)
2.9
2.9
Y381 (6)
S109 (3)
2.9
2.9
Antagonists
QNB
Agonists
ACh
 
 
Fig.27 Comparison of the agonist and antagonist binding. The 
interhelical hydrogen bond between Tyr 381 on TM 6 and Ser 109 on 
TM3 is broken when agonists bind.  
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Fig. 29 Comparison of calculated binding energies all the 10 ligands used 
in this study with the experimental dissociation constants for the M1 
receptor. Here a more positive energy indicates stronger binding. No 
corrections to the binding energies were made for zero-point energy, 
dynamics, or entropy.  
 
B 
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Fig. 30  Energetic rotational scan of TM1. The energy values (in blue) are scaled 
so that the best are at the outer circle. The energies become progressively 
worse closer to the center. Only the negative energy values are plotted. 
Therefore, if a particular rotational angle has a positive value in energy, it is 
plotted as zero (in the center of the plot). The red line represents the number of 
hydrogen bonds in the structure with the outer circle having the maximum 
number of hydrogen bonds. Both the maximum number of hydrogen bonds and 
lowest energy happen at degree zero for TM1, which corresponds to orientation 
in the final structure reported. There is no salt bridge between TM 1 to the other 
TMs. 
 
Fig. 31  Energetic rotational scans of TM1 with only the top 1/3 of the lowest 
energy values plotted to highlight the energy minimums.  The energy values 
(in blue) are scaled so that the best are at the outer circle. The energies 
become progressively worse closer to the center.  
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Fig. 32  Energetic rotational scans of TM2. The final structure 
corresponds to the zero degree rotational orientation.  
 
Fig. 33  Energetic rotational scans of TM2 with only the top 1/3 of the 
lowest energy values plotted to highlight the energy minimums.   
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Fig. 34 Energetic rotational scans of TM3. Only the negative energy values 
are plotted. Therefore, if a particular rotational angle has a positive value in 
energy, it is plotted as zero (in the center of the plot). Both the 20 degree and 
the zero degree conformation were docked. The final structure corresponds 
to the 20 degree rotational orientation.  
 
Fig. 35 Energetic rotational scans of TM3 with only the top 1/3 of the 
lowest energy values plotted to highlight the energy minimums. 
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Fig. 36  Energetic rotational scans of TM4. The final structure corresponds to the 
zero degree rotational orientation.  
 
Fig. 37  Energetic rotational scans of TM4 with only the top 1/3 of the lowest 
energy values plotted to highlight the energy minimums.   
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Fig. 38  Energetic rotational scans of TM5. The final structure 
corresponds to the zero degree rotational orientation.  
 
Fig. 39  Energetic rotational scans of TM5 with only the top 1/3 of the 
lowest energy values plotted to highlight the energy minimums.  The two 
minimums (0 and 90 degree) seem to correspond to mutations that 
selectively affect antagonists binding (ground state) and agonists 
binding (activated) state, respectively, 
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Fig. 40  Energetic rotational scans of TM6. The final structure 
corresponds to the zero degree rotational orientation. The energies of the 
rotational angles from 140-165 degrees are too large (due to bad van der 
Wall clashes) to be plotted. 
 
Fig. 41  Energetic rotational scans of TM6 with only the top 1/3 of the 
lowest energy values plotted to highlight the energy minimums.   
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Fig. 42  Energetic rotational scans of TM7. The final structure corresponds to 
the zero degree rotational orientation.  
 
Fig. 43  Energetic rotational scans of TM7 with only the top 1/3 of the lowest 
energy values plotted to highlight the energy minimums. 
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Part 2: Cation-π Interactions at the Nicotinic 
Acetylcholine Receptor Binding Site: A Quantum 
Mechanical Study 
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A b s t r a c t  
 
Cation-π interactions play a critical role in ligand binding and recognition in 
nicotinic acetylcholine receptors as well as many other biological systems. However, 
conventional force fields do not describe cation-π interactions accurately.  We used high-
level quantum mechanics with a high quality basis set to quantify the cation-π interactions 
in the environment of a protein using coordinates extracted from the crystal structure of 
carbamylcholine binding to Acetylcholine-binding Protein, a water-soluble homolog of the 
ligand binding domain of nicotinic receptors. Specifically, we extracted the 
carbamylcholine quaternary ammonium head group and the five aromatic sidechains 
interacting with it as our model system to calculate the binding energy contribution of each 
residue with X3LYP/B3LYP DFT methods. The results show that Tyr 192 and Trp 143 
contribute the most (accounting for 31% and 29%, respectively) to the binding of the ligand 
head group, followed by Trp 53 (23%) and Tyr (17%), while Tyr 89 does not contribute in 
binding energy. In addition, we calculated the effect of fluorinated Trp 143 on binding and 
observed a decrease in binding energy with each additional fluorine substitution as it 
decreases the ability of Trp 143 to form cation-π interactions.  The predicted change in 
binding energy correlates excellently with the experimental data in nicotinic acetylcholine 
receptor. Our results suggest that quantum mechanics can accurately predict cation-π 
bindings in a protein environment and provide a good model system in developing force 
fields to better describe cation-π interactions.  
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C h a p t e r  4  
 
CATION-π INTERACTIONS AT THE 
NICOTINIC ACETYLCHOLINE RECEPTOR 
BINDING SITE: A QUANTUM MECHANICAL 
STUDY 
 
Introduction 
 
The cation-π interaction is an important, general force for protein stability (1), 
protein folding (2), and molecular recognition in biological receptors, including both the 
nicotinic and muscarinic receptors (3). It is most strongly influenced by electrostatic forces, 
involving the interaction of a cation with the large, permanent quadrupole moment of an 
aromatic ring (1). Quantum mechanics were used to study the cation-π interactions between 
individual aromatic side chains and the cation-containing heterocyclic ring fragments of 
nicotinic ligands (1, 3). However, these pair-wise studies do not provide a holistic view of 
how the acetylcholine quaternary ammonium head group is stabilized in the environment of 
an aromatic cage, how many aromatic residues are needed, and how much each aromatic 
side-chain contributes to ligand binding.  
 
  
77 
Fortunately in 2004, the crystal structure of carbamylcholine binding to 
Acetylcholine-binding Protein (AChBP), a water-soluble homolog of the ligand binding 
domain of nicotinic receptors, became available (4). AChBP is found in the snail Lymnaea 
stagnali. It is produced and stored in glial cells, and released in an acetylcholine-dependent 
manner into the synaptic cleft, where it modulates synaptic transmission. AChBP is 210 
residues long and forms a stable homopentamer.  Nearly all residues conserved within the 
nicotinic acetylcholine receptor family are present in AChBP, including the ones that are 
relevant for ligand binding. Moreover, AChBP binds known agonists and antagonists (such 
as acetylcholine, nicotine, d-tubocurarine and α-bungarotoxin) of nicotinic receptors (5), so 
AChBP has been used extensively as a model system to understand the nicotinic receptor 
binding site. The availability of the carbamylcholine-AChBP complex crystal structure 
enabled us to examine, in the context of a protein, the cation-π interactions at the nicotinic 
receptor binding site with quantum mechanical methods.  
  
In addition, we calculated the effect of unnatural amino acids substitutions that were 
incorporated into the nicotinic receptor binding site using the in vivo nonsense-suppression 
method (6). We found an excellent correlation between the calculated binding energies and 
the experimental EC 50 results. The knowledge we learned from this study is instrumental 
in the prediction and refinement of the M1 muscarinic receptor binding site. It also 
provides a good model system for developing force fields that can better describe cation-π 
interaction in proteins. 
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Computational Methods 
Structure Preparation 
The protein structure used in this study was extracted from the 2.5 Å crystal structure (4) of 
carbamylcholine binding to Acetylcholine-binding Protein (PDB code: 1UV6), a water-
soluble homolog of the ligand binding domain of nicotinic receptors (Fig. 1). The 
coordinates extracted include the carbamylcholine quaternary ammonium head group and 
the five aromatic side chains interacting with the head group. The hydrogen atoms were 
added to the PDB file and the β carbon of each side chain was modeled as a methyl group. 
We then optimized the hydrogen positions using conjugate gradient minimization and TVN 
molecular dynamics while keeping all the non-hydrogen atoms fixed in order to preserve 
the original crystal structure. The final structure used in this study is shown in Fig. 2. There 
are a total of 103 atoms in the system.  
  
Binding Energy Calculations with Quantum Mechanical Methods 
We used high-level quantum mechanics, the density-functional theory (DFT) methods, and 
a high quality basis set, ccpv-tz(-f) and 6-31G**, to accurately calculate the binding energy 
contribution of each aromatic side chain. Two DFT methods were used: the standard Becke 
three parameter Lee-Yang-Parr (B3LYP) and an enhanced extended hybrid density 
functional method (X3LYP) recently developed by our group. This method has been shown 
to significantly improve the accuracy for hydrogen-bonded and van der Walls complexes 
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(7). The following section explains how we calculated the binding energy contribution of 
each aromatic side chain in the complex using Trp 143 as an example: 
(1) BE (the whole complex) = PE (the whole complex) – PE (the five aromatic sidechains 
only) – PE (the ligand head group) 
 
(2) BE (the whole complex with Trp 143 removed) = PE (the whole complex with Trp 143 
removed) – PE (the four aromatic sidechains only, with Trp 143 removed) – PE (the ligand 
head group) 
 
(3) BE (contribution from Trp 143) = BE (the whole complex) - BE (the whole complex 
with Trp 143 removed) 
 
BE stands for binding energy and PE stands for potential energy. The energy calculations 
were conducted for each aromatic side chain without solvation. We also calculated the pair-
wise interaction energy between the ligand head group and each aromatic side chain as 
follows: 
BE (pair-wise) = PE (the ligand and sidechain pair) – PE (the ligand) – PE (the sidechain) 
 
Unnatural Amino Acid Substitutions 
  
80 
We substituted Trp 143 (which corresponds to Trp 149 in nicotinic receptors) with a 
series of fluorinated substituents: 5-F-Trp; 5,7-F2-Trp; 5,6,7-F3-Trp; and 4,5,6,7-F4-Trp. 
We calculated the binding energy contributions of these fluorinated Trp substitutions and 
compared the results to experimental EC50 data (6).  
 
Results and Discussions 
Fig. 3 lists the calculated pair-wise binding energy between each individual 
aromatic sidechain and the ligand head group. Fig. 4 lists the binding energy contribution 
of each aromatic sidechain in the protein complex. Two DFP methods (X3LYP and 
B3LYP) and two different basis sets (cc-pvtz-(f) and 6-31g**) were used to calculate the 
binding energy. Fig. 3 and Fig. 4 show that these methods gave similar results, although 
X3LYP consistently gave a slightly larger binding energy than B3LYP did, given the same 
basis set.  The X3LYP was shown in other systems to outperform B3LYP in describing van 
der Waals and hydrogen bond interactions (7). The better binding energy from X3LYP 
observed in our system reflects X3LYP’s ability to better describe the attractive part of the 
van der Walls energy.  Because cc-pvtz(-f) is a larger basis set than 6-31g**,  we also 
consider the results from cc-pvtz(-f) more accurate than 6-31g**.  
 
Fig. 5 compares the binding energy contribution of each aromatic sidechain in 
the complex and the pair-wise binding energy, both calculated by X3LYP/cc-pvtz(-f) 
methods. The two sets of results show a similar trend in the relative importance of each 
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aromatic residue in ligand binding, although the value of the binding energy is 1 to 2 
kcal/mol smaller in the complex than in pair-wise calculations due to the interactions 
among the aromatic sidechains in the complex.  
 
The results show that in the crystal structure complex, Tyr 192 and Trp 143 
contribute the most (accounting for 31% and 29%, respectively) to binding the ligand head 
group, followed by Trp 53 (23%) and Tyr (17%), while Tyr 89 does not contribute  (Fig. 
6).  The ligand-sidechain pair gave similar results in binding energy contributions: Trp 143 
(28%), Tyr 192 (26%), Trp 53 (23%), Tyr 185 (19%), and Tyr 89 (4%) (Fig. 6).  
 
Mutagenesis studies suggested that the hydroxy group of the Tyr residue equivalent 
to Tyr 89 in AChBP is essential for high affinity acetylcholine binding in nicotinic 
acetylcholine receptors (8). However, when we mutated Tyr 89 to Phe and recalculated its 
binding energy contribution, we observed that the Phe substitution actually increased the 
binding energy slightly, while experimentally it significantly reduced acetylcholine binding 
affinity (8, 9). Our result suggests that this effect did not result from the cation-π 
interactions between Tyr 89 and the acetylcholine head group. The hydroxy group of Tyr 
89 is hydrogen bonded to a main chain carbonyl group in the AChBP-carbamylcholine 
crystal structure complex (4). Tyr 89 might influence ligand binding by affecting the 
aromatic packing at the nicotinic receptors binding site, and this hydrogen bond might be 
important in keeping Tyr 89 at its current conformation.  
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Because of the importance of Trp 143 in ligand binding and the availability of 
experimental data of unnatural amino acid substitutions in nicotinic acetylcholine receptors, 
we calculated, in the complex, the effect of fluorinated Trp 143 on ligand binding. We 
observed a decrease in binding energy with each additional fluorine substitution as it 
decreased the ability of Trp 143 to form cation-π interactions.  Fig. 7 shows that the 
predicted change in binding energy in the complex correlates excellently (R square = 0.98) 
with the experimental EC 50 data in the nicotinic acetylcholine receptor (6). Our results 
suggest that quantum mechanics (B3LYP/6-31g** or higher) can accurately predict cation-
π bindings in a protein environment. The results also suggest that four aromatic sidechains 
are sufficient to stabilize the acetylcholine head group in the nicotinic receptor’s binding 
site because the 5th ring, Tyr 89, contributes very little to the binding energy.  
 
Conclusion 
This quantum mechanical study provides a quantitative description of each 
aromatic residue’s contribution in stabilizing the acetylcholine head group in the nicotinic 
receptor binding site. The result correlates excellently with the experimental EC 50 data 
where unnatural amino acids were incorporated, suggesting that quantum mechanics can 
accurately predict cation-π bindings in a protein environment. We hope that our results will 
not only lead to a better understanding of cation-π interactions critical to acetylcholine 
binding but also provide a good model system for future development of force fields to 
better describe cation-π interactions in proteins.  
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Fig. 1 The crystal structure of carbamylcholine binding to
Acetylcholine-binding Protein.  
Fig. 2 The structure extracted as our model system.
Hydrogen atoms are added to the structure.
W53W53
W143 W143 Y192Y192
Y185 Y185
Y89
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 Fig. 4 The binding energy contribution of each aromatic side chain fragment in the complex.  
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Fig. 6 The binding energy contribution of each aromatic side chain fragment in 
the complex and in ligand-side chain fragment pairs based on the X3LYP/ cc-
pvtz(-f) calculation results. 
 
In Complex In Ligand-fragment Pair 
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Fig. 7 Comparison of the changes in ligand binding energy from the 
widetype due to the fluorinated Trp substitutions (calculated by B3LYP/6-
31g**) and the experimental EC50 values. The change (the amount of 
binding energy decreases) is shown in positive values where a larger 
number indicates a larger decrease in binding energy.  
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Part 3 Designing pH Responsive Proteins with Unnatural 
Histidines 
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A b s t r a c t  
 
Histidine is known to modulate protein-protein interactions in a pH dependent 
manner. For example, the neonatal Fc receptor (FcRn) transports immunoglobulin G (IgG) 
across epithelia, binding to IgG in acidic vesicles (pH <6.5) and releasing IgG in the blood 
at pH 7.4. We designed a series of histidine derivatives by substituting the 2, 4, or both 
positions on the histidine imidazole ring with a number of functional groups (e.g. –CH3, F, 
Cl) that are small in size and lack the ability to form hydrogen bonds. Quantum mechanical 
calculations of the acid dissociation constants (pKa) show that these functional groups shift 
the histidine pKa upward or downward through electron donating or withdrawing 
capabilities. We report a list of histidine derivatives and their corresponding pKa values 
that can be used in various applications including drug design for tumor specificity (e.g. 
HER2-Herceptin antibody), drug delivery through pH sensitive hydrogels, drug recycling, 
catalysis, and biosensors development. An example of how these unnatural histidines can 
be used is illustrated with 2-methyl histidine incorporated in a c-Myc-Max heterodimer.  
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C h a p t e r  5  
INTRODUCTION TO THE DESIGN CONCEPT 
 
Monoclonal antibodies have been used extensively in cancer therapy. Although 
these monoclonal antibodies are generally very specific for their targets, they tend to elicit 
certain side effects by binding to non-tumor tissue, often because their targets are not 
specifically expressed on tumor cells, but are also expressed (although in smaller numbers) 
on some healthy cells. Such side effects are generally undesirable, and there is a need for 
antibodies with an improved specificity. One such example is the monoclonal antibody 
Herceptin (Trastuzumab) against breast cancer (1).  Herceptin binds to the human 
epidermal growth factor Type II receptor (HER-2/neu, the c-erbB2 gene product). It has a 
serious side effect that damages the hearts of patients, partly due to the expression of HER-
2/neu receptors on both tumor cells and normal heart cells.  
 
The pH of human blood is highly regulated and maintained in the range of 7.4-7.8, 
whereas the extracellular environment of tumor cells is more acidic (pH of 6.3-6.5) because 
of the accumulation of metabolic acids that are inefficiently cleared due to poor tumor 
vascularization (2). If the interaction between a tumor antigen and its therapeutic antibody 
can be modulated such that at low pH, the binding is favored, the tumor-antibody may have 
an added specificity for those tumor antigens, even though the same tumor antigens are also 
found on normal tissues.   
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Histidine is known to modulate protein-protein interactions in a pH dependent 
manner. For example, the neonatal Fc receptor (FcRn) transports immunoglobulin G (IgG) 
across epithelia, binding to IgG in acidic vesicles (pH <6.5) and releasing IgG in the blood 
at pH 7.4. FcRn binds to Fc with high affinity at lower pH when the Fc histidines 310, 435, 
436 are positively charged, and releases Fc upon their deprotonation at higher pH (3). This 
concept was successfully used in rational drug design to increase the lifetime and potency 
of granulocyte colony-stimulating factor (GCSF) by mutating selected residues to 
histidines (4). The design of the GCSF mutant was based on the principle that neutral 
histidines could maintain relatively tight binding on the cell surface (pH > 7), but 
protonated histidines could lead to weaker binding in endosomal compartments (pH 
between 5 and 6), which results in increased recycling to the cell surface (4). 
 
Protein engineering is a powerful tool for modification of the structural, catalytic 
and binding properties of proteins. The incorporation of unnatural amino acids can greatly 
extend the scope and impact of protein engineering methods.  Unnatural amino acids can be 
incorporated into proteins by various methods including chemical synthesis, nonsense 
suppression methods (5), or by utilizing a modified aminoacyl-tRNA synthetase (6). We 
designed a series of unnatural histidines that can be incorporated into proteins for pH-
sensitive binding. It is known in organic chemistry that the strengths of a series of 
substituted benzoic acids are different from the strength of benzoic acid itself. The extent of 
the effect is correlated with the electron withdrawing or donating capabilities of the 
substituents (7). We applied this concept in designing a series of histidine derivatives by 
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substituting the 2, 4, or both positions on the histidine imidazole ring with a number of 
functional groups (e.g. –CH3, F, Cl) that are small in size and lack the ability to form 
hydrogen bonds. Quantum mechanical calculations of the acid dissociation constants (pKa) 
show that these functional groups shift the values of histidine pKa upward or downward 
based on their electron donating or withdrawing capabilities. In the next chapter, we report 
a list of unnatural histidines and their corresponding pKa values ranging from -8.4 to 8.2 
(an enormous difference of more than 1016), with 18 different values in between. These 
unnatural histidines and their combinations can be used in a wide range of applications 
including drug design for tumor specificity as we described above, drug delivery through 
pH sensitive hydrogels, drug recycling, catalysis, and biosensors development.  An 
exemplary application of these histidine analogs is illustrated with 2-methyl histidine, 
which shifts the pKa value up for about 1 unit, incorporated in a c-Myc-Max heterodimer. 
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C h a p t e r  6  
 
ACID DISSOCIATION CONSTANTS OF UNNATURAL HISTIDINES AND AN 
EXEMPLARY APPLICATION 
 
The Acid Dissociation Constants of Imidazole Derivatives 
We conducted quantum mechanical calculations to derive the acid dissociation 
constants (pKa) of a series of imidazole derivatives using the Schrödinger’s pKa prediction 
module in JaguarTM 5.5 software. The detailed algorithm is described in the Jaguar User 
Manual (8) and summarized below.  The following thermodynamic cycle was used to 
calculate the pKa value of a molecule in aqueous solution. 
 
 
 
 
 
The pKa is related to D by  
pKa = (1 / 2.3 R T) D   and 
A  = Δ H – T Δ S  = E B (g) – E BH+ (g) + 5 / 2 R T – T Δ S 
The algorithm calculated parts A, B, and C of the above cycle and D can be obtained by 
 
  
94 
summing the free energy changes for these three components and the experimental 
value of –259.5 kcal/mol for the solvation free energy change of a proton. 
 
To investigate the accuracy of our methods in predicting the pKa values of 
imidazole variants, we calculated the pKa of a series of imidazole derivatives listed in 
Fig. 2 and compared our results to the experimental pKa values (9, 10). Fig. 1 shows the 
imidazole structure and lists the positions of substitutions on the imidazole referred to in 
Fig. 2. Fig. 2 shows that our methods are very accurate in predicting the experimental 
pKa values of these imidazole derivatives and suggests that no further adjustments of the 
calculated results are needed to accurately predict the experimental pKa values (9, 10).  
 
We then substituted the hydrogens at the 2, 4, or both positions of the imidazole 
ring with the functional groups listed in Table 1.  These functional groups were selected 
because they are relatively small in size and lack the ability to form strong hydrogen 
bonds that could affect protein binding. Our calculations suggest that these groups shift 
the imidazole pKa upward or downward depending on their electron donating or 
withdrawing capabilities. Table 1 lists the calculated pKa values of these imidazole 
derivatives. It is apparent that, even with the limited choice of just 6 types of small 
functional groups (e.g. -CN, -F, -Cl, -CH2F, -OCH3, or -CH3), and two potential 
substitution positions (position 2 or 4 on the imidazole ring), the pKa of the resulting 
imidazole derivatives can range from a low of -7.1 to a high of 8.5, with 18 different 
values in between.  A combination of these functional groups is expected to create more 
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pKa values.  
The Additive Effect of 2, 4 Substitutions 
Table 1 shows that for a given functional group, the pKa change in 2, 4 double 
substitutions are approximately the sum of the pKa changes by 2 and 4 single substitutions. 
For example, 2-CN-imidazole changed the imidazole pKa 7.1 units (from 6.9 to -0.2) and 
4-CN-imidazole changed the pKa 6.6 units (from 6.9 to 0.3). The pKa of 2, 4-CN-
imidazole is -7.1, which is a 14 units change and approximately equal to the changes of 2-
CN and 4-CN substitutions combined. We observed similar trends for all other functional 
groups studied, suggesting that the electronic withdrawing or donating effect of 2, 4 
substitutions are additive (Table 1). This result suggests that we can create more pKa 
values by substituting different functional groups at the 2, 4 positions of imidazole and we 
can estimate these pKa values from the single substitution results. This additive effect was 
verified by the published experimental pKa of various imidazole derivatives (9, 10). For 
example, the pKa changes (ΔpKa) in 2, 4-di-CH3 and 2, 4-di-nitro are approximately equal 
to ΔpKa of the 2 and 4 single substitution combined. This further validates the accuracy of 
our calculations.  
 
The Acid Dissociation Constants of Histidine Analogs 
We conducted similar quantum mechanical calculations to derive the pKa of a 
series of histidine derivatives. The structure of the histidine molecule is shown in Fig. 3. 
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We extended the histidine molecule to include the adjacent two α-carbon atoms in the 
protein backbone. The backbone was built in an α-helical conformation (which 
corresponds to the conformation in a leucine zipper). The structure was minimized with 
implicit solvent described by the surface Generalized Born (GB) continuum solvent model 
(11) before the quantum mechanical pKa calculations.  
We substituted the hydrogens at the 2, 4, or both positions of the histidine 
imidazole ring with the same set of functional groups as the ones used in imidazole. As 
we mentioned earlier, these functional groups were selected because they are relatively 
small in size and lack the ability to form strong hydrogen bonds that could affect protein 
binding. The pKa was calculated for position 3 of the imidazole ring (Fig. 1 and Fig. 3). 
Our calculations suggest that these groups shift the histidine pKa (6.0 in experimental 
measurement and 5.8 in our calculation) upward or downward depending on their 
electron donating or withdrawing capabilities. Table 2 lists the calculated pKa values of 
the unnatural histidines that can be used in various applications to control pH-responsive 
protein binding. It is apparent that, even with the limited choice of just 6 types of small 
side-chain groups (e.g. -CN, -F, -Cl, -CH2F, -OCH3, or -CH3), and two potential 
substitution positions (position 2 or 4 on the imidazole ring) of a single natural amino 
acid (e.g. histidine), the side-chain pKa of the resulting histidine analog can range from a 
low of -8.4 to a high of 8.2 (an enormous difference of more than 1016), with 18 different 
values in between. A combination of different small side-chain groups at different ring 
positions is expected to create more pKa values. 
Compared with a single value (pKa = 5.8) of the natural histidine residue, this 
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range greatly expanded the possibility of modulating pH-sensitive binding of a protein 
bearing such an unnatural amino acid. 
 
Comparison of ΔpKa in His and Imidazole Derivatives 
Table 3 compares the ΔpKa in His (pKa = 5.8) and imidazole (pKa = 6.9) and 
shows that the ΔpKa for each functional group is very similar in His and imidazole. This 
suggests that the same substitution might change the pKa for a similar magnitude in a 
protein, too, allowing us to estimate the ΔpKa of a specific substitution in a protein using 
Table 3.  
The only major difference of ΔpKa in imidazole and His is observed in 4-OCH3 
substitutions. Detailed examination of the quantum mechanical geometry optimization 
results (the first step in pKa calculation in Jaguar) revealed that in 4-OCH3-His, the OCH3 
functional group was prevented from moving to the same, lower energy, conformation as in 
imidazole because of the steric hindrance of the protein backbone. The OCH3 functional 
group, unlike other functional groups selected, has an additional torsion angle. The 
conformational flexibility of OCH3 might affect the pKa value when incorporated into a 
protein and should be used with caution. 
  
98 
 
Incorporating 2-Methyl Histidine in the c-Myc-Max Heterodimer 
Next, we substituted the histidine at the center of the c-Myc-Max heterodimeric 
leucine zipper (at position 8d of the helical wheel on Max in Fig. 4) with an unnatural 
histidine where its hydrogen atom at the 2 position of the imidazole ring was substituted 
with a methyl group. After we incorporated the 2-methyl histidine, we sampled the 
histidine rotamer library to calculate the energy of each conformation. Each structure was 
independently optimized with energy minimization in implicit solvent using the surface 
Generalized Born continuum solvent model. We also added counter ions to neutralize the 
system. The charges used for these histidine analogs were first derived from quantum 
mechanics calculations and then fitted to the CHARMM charges, so we can describe the 
backbone of all the residues in the leucine zipper with the same set of charges. We found 
that the lowest energy rotamer for 2-methyl histidine has the same conformation as the 
wild-type histidine in the NMR structure (12). The quantum mechanical pKa calculations 
(Table 3) suggest that this substitution will shift the histidine pKa (7.19 ± 0.03 
experimental value (13)) up for about 1.1-1.4 units in the particular context of the leucine 
zipper.  
Fig. 5 shows the positions of the wildtype and the 2-methyl histidines and their 
surrounding residues (within 5 Å) on c-Myc, including Glu 5, Leu 8, Ile 9, and Glu 12. 
To understand quantitatively how 2-methyl histidine interacts with its surrounding 
residues on c-Myc compared to the wildtype histidine, we calculated the interaction 
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energy between the histidine (in both its protonated and unprotonated form) and these 
residues.  Our analysis, summarized in Table 4, suggests that the 2-methyl histidine and 
the wildtype histidine have very similar effects on target protein binding in the zipper. 
However, the effect was achieved at different pH values due to the side-chain pKa 
differences, which illustrates and conforms with our design purposes. 
 
Conclusion  
In this study, we introduced a novel concept of using unnatural histidines to 
modulate pH dependent binding. We designed a series of histidine analogs and reported 
their calculated pKa values, ranging from -8.4 to 8.2 (an enormous difference of more than 
1016).  We illustrated the effect of incorporating one of these molecules, the 2-methyl 
histidine, into a leucine zipper c-Myc-Max heterodimer, which can be tested 
experimentally. As there are almost 100 industry related R & D projects utilizing 
conjugated antibodies for cancer therapy, we believe that the concept and the example 
described in this study will be very useful in designing drugs with improved tumor 
specificity, and in additional applications such as drug delivery, drug recycling, catalysis, 
and biosensors development.  
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Fig. 1 The structure of the imidazole ring. 
 
 Fig. 2 Comparison of the calculated pKa values and the experimental pKa 
values. The numbering of the position of substitutions on the imidazole ring 
corresponds to what was shown in Fig. 1. The data points (from left to right) 
correspond to substitutions of 2-Fl, 4-Cl-1-CH3, 5-Cl-1-CH3, wildtype 
imidazole, 1-CH3, 1-C2H5, 4-CH3, 2-CH3, 2-C2H5, 2,4-diCH3, 4, 5-diCH3, 2, 
4, 5-triCH3 imidazoles. 
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Fig. 3 The structure of the histidine. The numbers listed are the
positions of substitutions on the imidazole ring. Position 3 is the
protonation site where the pKa value was calculated.
3
2
1
4
5
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Fig. 4  The structure of the C-Myc-Max heterodimeric leucine zipper.
The histidine analog was incorporated to position 8d on the Max helix.
This histidine, when protonated, interacts with two glutamate residues
on c-Myc through electrostatic interaction.  The HCe1 proton (the
position 3 as shown in Fig. 3) of Max histidine 8d has a pKa vale of
7.19± 0.03. The C-Myc and Max helices are linked with a disulfide
bond in the NMR structure.
His 8d
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Glu 5 Glu 5
Glu 12Glu 12
Ile 9Ile 9
Leu 8 Leu 8
2.9 2.9
4.9 5.0
Fig. 5 Comparison of wildtype and 2-methyl histidine binding to the c-
Myc helix (in blue). The residues on c-Myc within 5 Å to the histidine
imidazole ring are illustrated. The lowest energy rotamer of 2-methyl
histidine and the wildtype histidine (in NMR structure) binds very
similarly to its surrounding residues on the c-Myc helix.  
 
  
5 
 
